Med. Pro Praxi 2009; 6(4): 187-190

Non-alcoholic fatty liver disease: Why to consider it?

MUDr. Dagmar Jackuliaková, prof. MUDr. Helena Vaverková CSc, prof. MUDr. Vlastimil ©čudla CSc
III. interní klinika FN a LF UP Olomouc

Non-alcoholic fatty liver disease (NAFLD) is worldwide the most common cause of chronic elevation of liver enzymes diagnosed by anamnesis

excluding abuse of alcohol (resp. when daily alcohol consumption do not exceed 20 g). It is necessary to exclude another cause

of liver disease. NAFLD is a clinicopathological term that encompasses a disease spectrum ranging from simple hepatic steatosis to

steatohepatitis, fibrosis, and cirrhosis, which may progress to liver failure or to develop to hepatocellular carcinoma. NAFLD is often

associated with insulin resistance and symptoms of metabolic syndrome. NAFLD reflects the coexistence of various cardiovascular risk

factors and shows the higher cardiovascular risk. Complex intervention of risk factors can prevent from the development of NAFLD.

Keywords: non-alcoholic fatty liver disease, insulin resistance, cardiovascular risk.

Published: September 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jackuliaková D, Vaverková H, ©čudla V. Non-alcoholic fatty liver disease: Why to consider it? Med. praxi. 2009;6(4):187-190.
Download citation

References

  1. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434-438.
  2. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989; 97: 1022-1024. Go to original source... Go to PubMed...
  3. Peters RL, Gay T, Reynolds TB. Post jejunoileal-bypass-hepatic disease. Am J Clin Pathol 1975; 63: 318-331. Go to original source... Go to PubMed...
  4. Cairns SR, Kark AE, Peters TJ. Raised hepatic free fatty acids in a patient with acute liver after gastric surgery for morbid obesity. J Clin Pathol 1986; 39: 647-649. Go to original source... Go to PubMed...
  5. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 1992; 87: 775-779.
  6. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002; 97: 2065-2069. Go to original source... Go to PubMed...
  7. Cairns SR, Kark AE, Peters TJ. Raised hepatic free fatty acids in a patient with acute fatty liver after gastric surgery for morbid obesity. J Clin Pathol 1986; 39: 647-649. Go to original source... Go to PubMed...
  8. McAvoy NC, Ferguson JW, Campbell IW, et al. Non-alcoholic fatty liver disease: natural history, pathology and treatment. Brit J Diabetes Vasc Dis 2006; 6: 251-260. Go to original source...
  9. Angulo P. Mechanisms of Disease. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231. Go to original source... Go to PubMed...
  10. Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94(10): 3010-3014. Go to original source... Go to PubMed...
  11. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-1219. Go to original source... Go to PubMed...
  12. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80. Go to original source... Go to PubMed...
  13. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419. Go to original source... Go to PubMed...
  14. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850. Go to original source... Go to PubMed...
  15. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30(6): 1356-1362. Go to original source... Go to PubMed...
  16. Fassio E, Álvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826. Go to original source... Go to PubMed...
  17. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-149. Go to original source... Go to PubMed...
  18. Malnick SDH, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM 2003; 96: 699-709. Go to original source... Go to PubMed...
  19. Nonomura A, Mizukami Y, Unoura M, et al. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992; 27(4): 521-528. Go to original source... Go to PubMed...
  20. Hultcrantz R, Glaumann H, Lindberg G, et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21: 109-113. Go to original source... Go to PubMed...
  21. Di Bisceglie AM. Nonalcoholic liver disease: an emerging view of its significance and management, medscape. http://www.medscape.com/viewarticle/434535.
  22. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98(5): 960-967. Go to original source... Go to PubMed...
  23. Browning J, Szczepaniak L, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395. Go to original source... Go to PubMed...
  24. Sheth SG, Gordon FD, Chopar S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-145. Go to original source... Go to PubMed...
  25. Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923. Go to original source... Go to PubMed...
  26. Araya QAV, Valera MJM, Contreras BJ, et al. Glucose tolerance alterations and frequency of metabolic syndrome among patients with non alcoholic fatty liver disease. Rev Med Chil 2006; 134(9): 1092-1098. Go to PubMed...
  27. Vozarova B, Stefan N, Lindsay RS, et al. High Alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 1889-1895. Go to original source... Go to PubMed...
  28. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 92: 73-79. Go to original source... Go to PubMed...
  29. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet. Med 2005; 22: 1129-1133. Go to original source... Go to PubMed...
  30. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109. Go to original source... Go to PubMed...
  31. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455. Go to original source... Go to PubMed...
  32. Marceau S, Biron S, Hould S, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-1517. Go to original source... Go to PubMed...
  33. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 129-134. Go to original source... Go to PubMed...
  34. Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999; 22: 2067-2071. Go to original source... Go to PubMed...
  35. Silverman JF, O'Brien KF, Long S, Leggett N, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349-1355.
  36. Adams LA, Lindor KD. Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought. Indian J Gastroenterol 2004; 23: 127-128.
  37. Ciba I, Widhalm K. The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. Acta paediactrica 2007; 96: 109-112. Go to original source... Go to PubMed...
  38. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in norhtern Italy. Ann Intern Med 2000; 132(2): 12-17. Go to original source... Go to PubMed...
  39. Brouwers MC, van Greevenbroek MM, Vermeulen VM, et al. Five-year follow-up of waist circumference, insulin and ALT levels in familial combined hyperlipidaemia. Clin Sci 2007; 113(9): 375-381. Go to original source... Go to PubMed...
  40. Younossi ZM. Review article: current management of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 2-12. Go to original source... Go to PubMed...
  41. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123(3): 745-750. Go to original source... Go to PubMed...
  42. Cortez-Pinto H, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis: clinocopathological comparison with alcoholic hepatitis in ambulatory a nd hospitalized patients. Dig Dis Sci 1996; 41: 172-179. Go to original source... Go to PubMed...
  43. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity. An autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110. Go to original source... Go to PubMed...
  44. Thomsen C, Becker U, Winkler K, et al. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994; 12: 487-495. Go to original source... Go to PubMed...
  45. Kotronen A, Yki-Jarvinen H. Fatty liver A novel component of the metabolic syndrome. Arterioscler. Thromb Vasc Biol 2008; 28(1): 27-38. Go to original source... Go to PubMed...
  46. Banerji MA, Buckley MC, Chaiken RL, et al. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relar Metab Disord 1995; 19(12): 846-850.
  47. Chang Y, Ryu S, Sung E, et al. Highier concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem 2007; 53(4): 686-692. Go to original source... Go to PubMed...
  48. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes. Diabetes care 2005; 28(7): 1757-1762. Go to original source... Go to PubMed...
  49. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761. Go to original source... Go to PubMed...
  50. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 117: 942-952. Go to original source... Go to PubMed...
  51. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. Hepatology 2003; 37: 343-350. Go to original source... Go to PubMed...
  52. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liv Dis 2001; 21: 27-41. Go to original source... Go to PubMed...
  53. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors p55 + p75 in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163. Go to original source... Go to PubMed...
  54. Letteron P, Fromenty T, Terris B, et al. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-208. Go to original source... Go to PubMed...
  55. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-133. Go to original source... Go to PubMed...
  56. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192. Go to original source... Go to PubMed...
  57. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69. Go to original source... Go to PubMed...
  58. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075. Go to original source... Go to PubMed...
  59. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver diesase. J Biol Chem 2004; 279: 32345-32353. Go to original source... Go to PubMed...
  60. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-1188. Go to original source... Go to PubMed...
  61. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10. Go to original source... Go to PubMed...
  62. Hotamisligil GS, Peraldi S, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668. Go to original source... Go to PubMed...
  63. Fan C-Y, Pan J, Usuda N, Yeldandi AV, et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase: implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998; 273: 15639-15645. Go to original source... Go to PubMed...
  64. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35(4): 898-904. Go to original source... Go to PubMed...
  65. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-1664. Go to original source... Go to PubMed...
  66. Bugianesi E, Pagotto U, Manini R, et al. Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. J Clin Endocrinol Metab 2005; 90(6): 3498-3504. Go to original source... Go to PubMed...
  67. Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152(1): 113-118. Go to original source... Go to PubMed...
  68. Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54(3): 603-608. Go to original source... Go to PubMed...
  69. Schattenberg JM, Wang Y, Singh R, et al. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280(11): 9887-9894. Go to original source... Go to PubMed...
  70. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-115. Go to original source... Go to PubMed...
  71. Lewis GF, Uffelman KD, Szeto LW, et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995; 95(1): 158-166. Go to original source... Go to PubMed...
  72. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol 1999; 84: 28J-32J. Go to original source... Go to PubMed...
  73. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-500. Go to original source... Go to PubMed...
  74. Comert B, Mas MR, Erdem H, et al. Insulin resistance in nonalcoholic steatohepatitis. Dig Liver Dis 2001; 33: 353-358. Go to original source... Go to PubMed...
  75. Deprés JP, Lamarche B, Mauriége P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957. Go to original source... Go to PubMed...
  76. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrom? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008; 31: 562-568. Go to original source... Go to PubMed...
  77. Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008; 121: 72-78. Go to original source... Go to PubMed...
  78. Akabame S, Hamaguchi M, Tomiyasu K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 2008; 72(4): 618-625. Go to original source... Go to PubMed...
  79. Brea A, Mosquera D, Martín E, et al. Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 1045-1050. Go to original source... Go to PubMed...
  80. Alper AT, Hasdemir H, Şahin S, et al. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Türk Kardiyol Dern Arş 2008; 36: 376-81. http://www.tkd.org.tr/english.asp?pg=:dergi/dergi_content&plng=eng&id=1708& dosya=166. Go to PubMed...
  81. Schindhelm RK, Diamant M, Dekker JM, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006; 22(6): 437-443. Go to original source... Go to PubMed...
  82. Meisinger C, Döring A, Schneider A, et al. KORA Study Group. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis. 2006; 189(2): 297-302. Go to original source... Go to PubMed...
  83. Adams LA, Lymp J, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005; 129: 113-121. Go to original source... Go to PubMed...
  84. Luyckx FH, Desaive c, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-226. Go to original source... Go to PubMed...
  85. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413. Go to original source... Go to PubMed...
  86. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weihgt loss. Hepatology 2004; 39: 1647-1654. Go to original source... Go to PubMed...
  87. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006; 4(5): 639-644. Go to original source... Go to PubMed...
  88. Blackburn GL, Mun EC. Effect of weight loss surgeries. Semin Liver Dis 2004; 24: 371-379. Go to original source... Go to PubMed...
  89. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23(8): 1143-1151. Go to original source... Go to PubMed...
  90. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, et al. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23(11): 1643-1647. Go to original source... Go to PubMed...
  91. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-1467. Go to original source... Go to PubMed...
  92. Marchesini G, Brizi M, Bianchi G, et al. Metformin in nonacoholic steatohepatitis. Lancet 2001; 358: 893-894. Go to original source... Go to PubMed...
  93. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-525. Go to original source... Go to PubMed...
  94. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-718. Go to original source... Go to PubMed...
  95. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39(3): 770-778. Go to original source... Go to PubMed...
  96. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-1672. Go to original source... Go to PubMed...
  97. Lavine JE. Vitamin E treatment of nonalcoholic stetohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-738. Go to original source... Go to PubMed...
  98. Adams LA, Zein CO, Angulo P, et al. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99(12): 2365-2368. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.